What is Teva Pharmaceutical Industries Cash, Cash Equivalents, Marketable Securities?
Teva Pharmaceutical Industries's quarterly cash, cash equivalents, marketable securities
declined
from Jun. 2023 ($2,669.00 Mil) to Sep. 2023 ($2,249.00 Mil) but then
increased
from Sep. 2023 ($2,249.00 Mil) to Dec. 2023 ($3,226.00 Mil).
Teva Pharmaceutical Industries's annual cash, cash equivalents, marketable securities
increased
from Dec. 2021 ($2,165.00 Mil) to Dec. 2022 ($2,801.00 Mil) and
increased
from Dec. 2022 ($2,801.00 Mil) to Dec. 2023 ($3,226.00 Mil).
Teva Pharmaceutical Industries Cash, Cash Equivalents, Marketable Securities Historical Data
The historical data trend for Teva Pharmaceutical Industries's Cash, Cash Equivalents, Marketable Securities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.
Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.
A high number means either:
1) The company has competitive advantage generating lots of cash
2) Just sold a business or bonds (not necessarily good)
A low stockpile of cash usually means poor to mediocre economics.
There are 3 ways to create large cash reserve.
1) Sell new bonds or equity to public
2) Sell business or asset
3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)
When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.
Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.
Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.
Teva Pharmaceutical Industries Cash, Cash Equivalents, Marketable Securities Related Terms
Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.
Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Business Description
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TEVA has been successfully added to your 